Literature DB >> 3317753

Tumor necrosis factor and interleukin 1 as mediators of endotoxin-induced beneficial effects.

R Urbaschek1, B Urbaschek.   

Abstract

Bacterial lipopolysaccharides or endotoxins are known to induce tumor necrosis; enhanced nonspecific resistance to bacterial, viral, and parasitic infections and to radiation sickness; and tolerance to lethal doses of endotoxin. These beneficial effects are achieved by pretreatment with minute amounts of endotoxin. Recombinant tumor necrosis factor (TNF) and interleukin 1 (IL-1) are among the mediators capable of invoking radioprotection or resistance to the consequences of cecal ligation and puncture. Both cytokines are potent inducers of serum colony-stimulating factor (CSF) in C3H/HeJ mice (low responders to endotoxin). The number of splenic granulocyte-macrophage precursors was found to increase 5 days after injection of TNF in these mice. Although with IL-1 no increase in the number of granulocyte-macrophage colonies occurred in culture in the presence of serum CSF, a marked stimulation was observed when TNF was added. This stimulation of myelopoiesis observed in vivo and in vitro may be related to the radioprotective effect of TNF. The data presented suggest that TNF and IL-1 released after injection of endotoxin participate in the mediation of endotoxin-induced enhancement of nonspecific resistance and stimulation of hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3317753     DOI: 10.1093/clinids/9.supplement_5.s607

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  11 in total

Review 1.  Infectious disease therapy in the 1990s. Where are we heading?

Authors:  M Rozenberg-Arska; M R Visser
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

2.  Glomerular inflammation induces resistance to tubular injury in the rat. A novel form of acquired, heme oxygenase-dependent resistance to renal injury.

Authors:  B A Vogt; T P Shanley; A Croatt; J Alam; K J Johnson; K A Nath
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

3.  Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1.

Authors:  T K Held; X Weihua; L Yuan; D V Kalvakolanu; A S Cross
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

4.  The role of IL-1β in nicotine-induced immunosuppression and neuroimmune communication.

Authors:  Seddigheh Razani-Boroujerdi; Raymond J Langley; Shashi P Singh; Juan Carlos Pena-Philippides; Jules Rir-sima-ah; Sravanthi Gundavarapu; Neerad C Mishra; Mohan L Sopori
Journal:  J Neuroimmune Pharmacol       Date:  2011-06-14       Impact factor: 4.147

5.  Protection of mice against Listeria monocytogenes infection by recombinant human tumor necrosis factor alpha.

Authors:  J V Desiderio; P A Kiener; P F Lin; G A Warr
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

6.  Immunochemical and structural analysis of the O polysaccharides of Salmonella zuerich [1,9,27,(46)].

Authors:  H O Nghiêm; K Himmelspach; H Mayer
Journal:  J Bacteriol       Date:  1992-03       Impact factor: 3.490

7.  Pathogenicity of Yersinia kristensenii for mice.

Authors:  R M Robins-Browne; S Cianciosi; A M Bordun; G Wauters
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

8.  Ciprofloxacin treatment in vivo increases the ex vivo capacity of lipopolysaccharide-stimulated human monocytes to produce IL-1, IL-6 and tumour necrosis factor-alpha.

Authors:  S Bailly; M Fay; B Ferrua; M A Gougerot-Pocidalo
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

9.  Exacerbation of toxic effects by endotoxin contamination of recombinant human tumor necrosis factor.

Authors:  Y Ozaki; T Oyama; S Kume
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 10.  Interleukin-1 and the response to injury.

Authors:  E Kaplan; C A Dinarello; J A Gelfand
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.